Selective LXR agonist, DMHCA, corrects the retina-bone marrow axis in type 2 diabetes is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2020). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 5R01EY028858-03
ACE2 Modulates the Bone Marrow- Gut Axis in Diabetic Retinopathy
National Institutes of Health
Grant: 5T32HL134640-03
UAB Predoctoral Training Program in Lung Diseases
National Institutes of Health
Grant: 2R01EY016077-08A1
Dyslipidemia and Diabetic Retinopathy
National Institutes of Health
Grant: 5R01EY025383-04
LXR as a Novel Therapeutic Target in Diabetic Retinopathy
National Institutes of Health
Grant: 5F32EY028426-03
The role of the SIRT1-LXR signaling axis in diabetes-induced cholesterol metabolism dysregulation
National Institutes of Health
Grant: 1R01EY030766-01
Anti-ceramide immunotherapy for diabetic retinopathy
National Institutes of Health
Grant: 2T32HL105349-11A1
UAB Pre-Doctoral Training Program in Obesity-Related Research
National Institutes of Health
Grant: 5R01EY028037-04
Somatostatin blockade of CNS autonomic hyperactivity for treatment of diabetic retinopathy
Fields of Study
Sustainable Development Goals